Search clinical trials for: 300 mg paracetamol and 30 mg codeine

Total 9632 results

Cerevel Therapeutics, LLC

Recruiting

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary
Vanderbilt University Medical Center

Completed

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

High Blood Pressure

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation

Influenza A Virus

Belgium
AstraZeneca

Completed

A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease

Parkinson's Disease

United States
GlaxoSmithKline

Completed

Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)

Multiple Sclerosis

Italy, Germany, Spain, United Kingdom, Australia, Netherlands, New Zealand, Russian Federation, France, Canada, Austria, Poland, Finland, Norway
Cognition Therapeutics
National Institute on Aging (NIA)

Completed

Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects (COG0108)

Alzheimer Disease

United States
Ardea Biosciences, Inc.

Completed

Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

Healthy

United States
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary, Puerto Rico, Ukraine
International Partnership for Microbicides, Inc.
National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaborators

Completed

PK Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel

Healthy | Contraception | Contraceptive Usage | Women

United States
Aquinox Pharmaceuticals (Canada) Inc.

Unknown

Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome (LEADERSHIP 301)

Interstitial Cystitis | Painful Bladder Syndrome | Bladder Pain Syndrome | Chronic Interstitial Cystitis

United States, Belgium, Canada, Czechia, Denmark, Hungary, Latvia, Netherlands, Poland, Romania, Spain, United Kingdom
Janssen Infectious Diseases BVBA

Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants

Healthy

United Kingdom
Morten Lindbaek
Norwegian Institute of Public Health; Sorlandet Hospital HF; Norwegian University...

Completed

Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice (NorTick_EM)

Lyme Disease | Erythema Migrans | Erythema Chronicum Migrans | Borreliosis | Early Lyme Disease

Norway
Intercept Pharmaceuticals

Active, not recruiting

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Primary Biliary Cholangitis

Netherlands, United Kingdom, Korea, Republic of, Germany, Australia, Estonia, Belgium, France, Czechia, Croatia, Greece, Hungary, Israel, Lithuania, Norway, Poland, Spain
Ain Shams University
Cairo University

Recruiting

Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children

HCV

Egypt
AstraZeneca

Completed

AZD5069 Neutrophil Function Study

Chemokine Receptor 2 (CXCR2) Antagonist

United Kingdom
Durect
CTI Clinical Trial and Consulting Services

Completed

A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis (AH)

Alcoholic Hepatitis

United States
Bill & Melinda Gates Medical Research Institute

Not yet recruiting

Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population

Healthy Volunteers

Kenya, Uganda
Dr. Reddy's Laboratories Limited
XenoPort, Inc.

Completed

A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

Psoriasis

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

China
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants

Healthy

Belgium
Gamaleya Research Institute of Epidemiology and...
Center of Pharmaceutical Analytics

Completed

An Open Study to Assess the Safety and Pharmacokinetics of Fluorothyazinone as a Single-Dose Administration or a Treatment Course in Healthy Volunteers

Healthy Volunteer

Russian Federation
Pfizer

Completed

First Safety Study in Humans of a Single Dose of CPG 52364

Healthy Volunteers

United States
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Gastric/Gastroesophageal Junction Cancer

China
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis (SCALP)

Chronic Scalp Psoriasis

United States
AmtixBio Co., Ltd.
Novotech (Australia) Pty Limited

Completed

A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis

Onychomycosis

New Zealand
GlaxoSmithKline

Completed

Single Dose Escalation First Time in Human PK Study

Infections, Bacterial

Australia
Merck Sharp & Dohme LLC

Completed

Initial Combination With Pioglitazone Study (0431-064)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Eli Lilly and Company

Completed

A Study of Galcanezumab in Participants With Chronic Cluster Headache

Chronic Cluster Headache

United States, Germany, France, Canada, Belgium, Denmark, Finland, Greece, Italy, Netherlands, Spain, United Kingdom
MedImmune LLC

Completed

A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers

Asthma | Healthy Subjects or Volunteers

United States
RespireRx
Duke University

Unknown

Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia

Opiate Induced Respiratory Depression

United States
CicloMed LLC
Cmed Clinical Services

Completed

Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

Influenza

United States
Novartis Pharmaceuticals

Withdrawn

An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound (INTERCEPT)

Psoriasis
Genzyme, a Sanofi Company
Worldwide Clinical Trials

Completed

Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer (Caprelsa104)

Symptomatic, Aggressive, Sporadic, Unresectable, Locally | Advanced/Metastatic Medullary Thyroid Cancer (MTC)

Belgium, Italy, Netherlands, Spain, France, Germany, United Kingdom, Luxembourg
University Hospital, Limoges

Completed

Description of the Evolution of Plasma and Urinary Concentrations of Iohexol in a Cirrhotic Patient Population (DFG HEP)

Cirrhosis Renal

France
Novartis Pharmaceuticals

Active, not recruiting

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Atherosclerotic Cardiovascular Disease

United States, China, South Africa, Spain, Austria, Belgium, Croatia, Estonia, Hungary, Taiwan, Turkey, Netherlands, Italy, Australia, Czechia, Denmark, France, Israel, Korea, Republic of, Thailand, Argentina, Bulgaria, Greece, Romania, Sloveni... and more
Takeda

Completed

Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema

Hereditary Angioedema

Japan
MedImmune LLC

Completed

A Phase 1, Open-label Study to Investigate the Pharmacokinetics of Tralokinumab (CAT-354) in Adolescents With Asthma

Asthma

Poland
Pfizer

Completed

A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers (PET)

Healthy

Sweden
Virginia Commonwealth University
AbbVie

Withdrawn

Venetoclax and Irinotecan in Relapsed/Refractory SCLC

Relapsed Small Cell Lung Cancer | Refractory Small Cell Lung Carcinoma
MedImmune LLC

Completed

A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma

Asthma

United States
Pfizer

Completed

A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects

Healthy Volunteers

Belgium
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

Influenza

United States
MedImmune LLC

Completed

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

Allergic Rhinitis | Healthy Volunteers | Atopic Dermatitis | Allergic Asthma

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants

Healthy

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Hypertension

United States, Belgium, Hungary, Turkey, Guatemala, Slovakia, Germany, Puerto Rico, Poland
AstraZeneca

Active, not recruiting

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Metastatic Triple Negative Breast Cancer

United States, Belgium, Italy, Spain, United Kingdom, Canada, Czechia, Poland, France, Korea, Republic of, Germany, Taiwan, Portugal, Netherlands, Ireland
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease

Huntington's Disease

Canada, United Kingdom, Germany
Janssen Inc.

Completed

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Psoriasis

United States, Poland, Canada, Belgium, Germany

Search clinical trials for: 300 mg paracetamol and 30 mg codeine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations